Published:
CorMatrix Cardiovascular to Present Data on Its Next Generation ECM Technology(TM) at Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference in Washington, D.C.
WASHINGTON, Oct. 10 /PRNewswire/ -- CorMatrix Cardiovascular, Inc., an
Atlanta-based company dedicated to developing and delivering unique
extracellular matrix (ECM(TM)) biomaterial devices that harness the body's
innate ability to repair damaged cardiovascular tissue, today announced that
Robert G. Matheny, M.D., Chief Scientific Officer, will present data on the
company's next generation ECM Technology(TM) at the annual Transcatheter
Cardiovascular Therapeutics (TCT) 2008 conference inWashington, D.C. next
week.
The presentation entitled "Cell Therapy Devices and Concepts: Acellular
Matrix Emulsion Injections to Induce Myofibroblast Proliferation and
Angiogenesis" will take place on Monday, October 13th at 1:35 p.m. EDT in room
145AB as part of the Innovative Devices and Futuristic Therapies Session.
"We are very proud to have Dr. Matheny included to present preclinical
data from our next generation product within this prestigious panel,"
commented Beecher Lewis, President and Chief Operating Officer of CorMatrix
Cardiovascular. "Our inclusion in this session reinforces the fact that our
technology continues to gain interest and acceptance among the cardiovascular
community."
About CorMatrix ECM Technology(TM)
CorMatrix Cardiovascular holds an exclusive license from Purdue University
to research, develop, manufacture and market naturally occurring ECM products
for cardiovascular applications. The company currently has U.S. clearance and
European approval with a CE Mark to market its ECM Technology as an implant
for pericardial closure, clearance in the U.S. for cardiac tissue repair, and
is conducting preclinical studies on a number of cardiovascular applications
including an emulsified, injectible form of its ECM Technology as a potential
treatment for heart failure.
About CorMatrix Cardiovascular, Inc.
CorMatrix Cardiovascular, a privately held company based inAtlanta,
Georgia, is dedicated to developing and delivering innovative biomaterial
devices that harness the body's own innate ability to regenerate damaged heart
tissue. For more information visit http://www.cormatrix.com.
SOURCE CorMatrix Cardiovascular, Inc.
Copyright © 2008, PRNewswire
Copyright © 2008, NewsBlaze,
Daily NewsTags: ,HEA,BIO,MTC,TDS,GA-CorMatrix-Conf
_ _Is your favorite bookmark site missing?
Ask for it.
Search News
Daily News
